Adjuvant pembrolizumab (AP) does not improve long-term cure vs surveillance + first-line ipilimumab/nivolumab (I/N) at recurrence in resected clear-cell renal cell carcinoma: a 3.36 million-patient Monte Carlo-based microsimulation